These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 14580776)

  • 81. E6a2 BCR-ABL fusion with BCR exon 5-deleted transcript in a Philadelphia positive CML responsive to Imatinib.
    Popovici C; Cailleres S; David M; Lafage-Pochitaloff M; Sainty D; Mozziconacci MJ
    Leuk Lymphoma; 2005 Sep; 46(9):1375-7. PubMed ID: 16109618
    [TBL] [Abstract][Full Text] [Related]  

  • 82. [The prognostic implications of secondary chromosomal aberrations in Philadelphia chromosome-positive chronic myeloid leukemia patients after imatinib mesylate treatment].
    Zhang Y; Jiang Q; Qiu JY; Chen SS; Jiang B; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2007 Aug; 46(8):648-50. PubMed ID: 17967235
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy.
    Atallah E; Talpaz M; O'brien S; Rios MB; Guo JQ; Arlinghaus R; Fernandes-Reese S; Kantarjian H
    Cancer; 2002 Jun; 94(11):2996-9. PubMed ID: 12115389
    [TBL] [Abstract][Full Text] [Related]  

  • 84. [Additional chromosomal abnormalities in dynamic of target therapy for chronic myeloid leukemia in children and adolescents].
    Andreeva SV; Drozdova VD
    Lik Sprava; 2014; (1-2):55-9. PubMed ID: 24908961
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Chronic myeloid leukemia in chronic phase responding to imatinib: the occurrence of additional cytogenetic abnormalities predicts disease progression.
    Marktel S; Marin D; Foot N; Szydlo R; Bua M; Karadimitris A; De Melo VA; Kotzampaltiris P; Dazzi F; Rahemtulla A; Olavarria E; Apperley JF; Goldman JM
    Haematologica; 2003 Mar; 88(3):260-7. PubMed ID: 12651263
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
    Kantarjian HM; Talpaz M; O'Brien S; Smith TL; Giles FJ; Faderl S; Thomas DA; Garcia-Manero G; Issa JP; Andreeff M; Kornblau SM; Koller C; Beran M; Keating M; Rios MB; Shan J; Resta D; Capdeville R; Hayes K; Albitar M; Freireich EJ; Cortes JE
    Clin Cancer Res; 2002 Jul; 8(7):2177-87. PubMed ID: 12114418
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate.
    Papaioannou G; Athanasiadou A; Voutiadou G; Gaitatzi M; Batsis I; Touloumenidou T; Anagnostopoulos A
    Cancer Genet; 2011 Dec; 204(12):692-3. PubMed ID: 22285023
    [No Abstract]   [Full Text] [Related]  

  • 88. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Usui N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Chronic lymphocytic leukaemia developing in the course of chronic myeloid leukaemia.
    Salim R; Wang L; Lin K; Clark RE
    Leuk Lymphoma; 2002 Nov; 43(11):2225-7. PubMed ID: 12533052
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Sudden blastic crisis and additional chromosomal abnormalities during chronic myeloid leukemia in the imatinib era.
    Ali R; Ozkalemkas F; Ozkocaman V; Yakut T; Nazlioglu HO; Budak F; Pekgoz M; Korkmaz S; Karkucak M; Ozcelik T; Tunali A
    Int J Clin Oncol; 2009 Dec; 14(6):545-50. PubMed ID: 19967494
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
    Ullmann AJ; Hess G; Kolbe K; Friedrich-Freksa A; Meyer RG; Gschaidmeier H; Huber C; Fischer T
    Keio J Med; 2003 Sep; 52(3):182-8. PubMed ID: 14529151
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Chronic myeloid leukemia with hyperdiploidy: a case report with review of literature.
    Belurkar S; Manohar C; Kurien A
    Indian J Med Sci; 2013; 67(7-8):188-92. PubMed ID: 24469564
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.
    Huntly BJ; Guilhot F; Reid AG; Vassiliou G; Hennig E; Franke C; Byrne J; Brizard A; Niederwieser D; Freeman-Edward J; Cuthbert G; Bown N; Clark RE; Nacheva EP; Green AR; Deininger MW
    Blood; 2003 Sep; 102(6):2205-12. PubMed ID: 12750153
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Successful childbirth in a patient with chronic myelogenous leukemia treated with imatinib mesylate during early pregnancy.
    Skoumalova I; Vondrakova J; Rohon P; Rozmanova S; Jarosova M; Indrak K; Prochazka M; Santava A; Faber E
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2008 Jun; 152(1):121-3. PubMed ID: 18795086
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta.
    Garcia JL; Font de Mora J; Hernandez JM; Queizan JA; Gutierrez NC; Hernandez JM; San Miguel JF
    Blood; 2003 Oct; 102(7):2699-700. PubMed ID: 14504072
    [No Abstract]   [Full Text] [Related]  

  • 96. Clonal chromosomal abnormalities in Philadelphia-negative cells in chronic myeloid leukemia patients treated with nilotinib used in first-line therapy.
    Wang H; Jin J; Wang Y; Huang X; Huang J
    Ann Hematol; 2013 Dec; 92(12):1625-32. PubMed ID: 23793947
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Prognostic importance of additional cytogenetic anomalies in chronic myeloid leukemia.
    Bozkurt S; Uz B; Buyukasik Y; Bektas O; Inanc A; Goker H; Kansu E
    Med Oncol; 2013 Mar; 30(1):443. PubMed ID: 23292838
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Bone marrow morphological changes in patients of chronic myeloid leukemia treated with imatinib mesylate.
    Joshi S; Sunita P; Deshmukh C; Gujral S; Amre P; Nair CN
    Indian J Cancer; 2008; 45(2):45-9. PubMed ID: 18626147
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Isolated central nervous system relapse in lymphoid blast crisis chronic myeloid leukemia and acute lymphoblastic leukemia in patients on imatinib therapy.
    Bujassoum S; Rifkind J; Lipton JH
    Leuk Lymphoma; 2004 Feb; 45(2):401-3. PubMed ID: 15101732
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Uncommon case of chronic myeloid leukemia with multiple myeloma.
    Ide M; Kuwahara N; Matsuishi E; Kimura S; Gondo H
    Int J Hematol; 2010 May; 91(4):699-704. PubMed ID: 20352382
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.